Merck KGaA Doesn’t Rule Out Pursuing Lung-Cancer Vaccine
May 17, 2013 | yahoo.com
Merck KGaA (MRK) hasn’t ruled out pursuing its therapeutic cancer vaccine L-BLP25 after a trial showed the treatment prolonged the lives of a group of advanced lung cancer patients by 50 percent compared with placebo. A group...
Read more...
Allison Connolly Merck vaccine KGaA L-BLP25 pursue patient Oncothyreon cancer rule